Holen Sie sich die Stockscreener-App
129.88
0.63%
0.76
Schlusskurs vom Vortag:
$129.12
Offen:
$129.57
24-Stunden-Volumen:
858.40K
Relative Volume:
0.56
Marktkapitalisierung:
$274.34B
Einnahmen:
$53.40B
Nettoeinkommen (Verlust:
$13.68B
KGV:
18.86
EPS:
6.8864
Netto-Cashflow:
$16.89B
1W Leistung:
-1.23%
1M Leistung:
+4.68%
6M Leistung:
+18.70%
1J Leistung:
+11.72%
1-Tages-Spanne:
$129.32
$129.98
1-Wochen-Bereich:
$128.83
$133.16
52-Wochen-Spanne:
$96.06
$133.55
Novartis Ag Adr Stock (NVS) Company Profile
Vergleichen Sie NVS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
129.87 | 249.96B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
LLY
Lilly Eli Co
|
814.34 | 747.19B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
188.00 | 459.32B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
228.88 | 406.84B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
MRK
Merck Co Inc
|
84.75 | 214.78B | 63.43B | 16.42B | 14.72B | 6.4861 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-12 | Herabstufung | Goldman | Neutral → Sell |
| 2025-08-08 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2025-02-13 | Herabstufung | UBS | Buy → Neutral |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Underweight |
| 2025-02-04 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-12-04 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2024-09-11 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-09-05 | Herabstufung | Goldman | Buy → Neutral |
| 2024-09-03 | Herabstufung | Jefferies | Buy → Hold |
| 2024-07-19 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-02-23 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Fortgesetzt | UBS | Buy |
| 2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-09-25 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-26 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2023-03-27 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2023-01-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-12-05 | Hochstufung | Stifel | Hold → Buy |
| 2022-09-15 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
| 2022-05-09 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2022-01-10 | Fortgesetzt | Citigroup | Buy |
| 2021-12-14 | Herabstufung | Redburn | Buy → Neutral |
| 2021-12-06 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2021-12-03 | Herabstufung | Bryan Garnier | Buy → Neutral |
| 2021-09-20 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2021-03-22 | Eingeleitet | Bernstein | Mkt Perform |
| 2021-03-10 | Herabstufung | Argus | Buy → Hold |
| 2021-02-01 | Herabstufung | Cowen | Outperform → Market Perform |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-09-10 | Hochstufung | UBS | Neutral → Buy |
| 2020-09-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-15 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-03-10 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2020-02-25 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-04-25 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-04-25 | Hochstufung | Liberum | Hold → Buy |
| 2019-04-10 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-01-02 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-12-11 | Fortgesetzt | Jefferies | Buy |
| 2018-10-09 | Eingeleitet | Guggenheim | Neutral |
| 2018-09-10 | Hochstufung | BofA/Merrill | Underperform → Buy |
| 2018-05-29 | Herabstufung | HSBC Securities | Buy → Hold |
| 2018-05-25 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-01-25 | Bestätigt | Leerink Partners | Outperform |
| 2017-12-06 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2017-07-26 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2017-07-05 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2017-03-09 | Eingeleitet | Liberum | Buy |
Alle ansehen
Novartis Ag Adr Aktie (NVS) Neueste Nachrichten
Will the Orbital Acquisition Strengthen BMY's Cell Therapy Portfolio? - The Globe and Mail
Mechanobiology-Centered Therapy Market Insights and Growth Outlook by Towards Healthcare - GlobeNewswire Inc.
UBS Reaffirms Their Hold Rating on Novartis AG (NOVN) - The Globe and Mail
Should You Buy Novartis Stock Before October 28? - Barchart.com
Barclays Reaffirms Their Sell Rating on Novartis AG (NOVN) - The Globe and Mail
2 Surefire Dividend Stocks to Buy for the Long Haul - sharewise.com
Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU) - Ariva
Novartis announces commencement of tender offer to acquire Tourmaline Bio - Novartis
Trump's New Tariff Barrage Targets Drugs, Trucks, Cabinets: President Says Move Will Protect Manufacturers From 'Unfair Outside Competition' - Sahm
Eli Lilly Stock Is Trading Down Thursday: What's Behind The Move? - Sahm
Novartis, AbbVie Face Legal Defeat Over 340B Contract Pharmacies - Sahm
INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream - The Globe and Mail
Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments - Sahm
Novartis (NVS) was downgraded to a Sell Rating at Goldman Sachs - The Globe and Mail
Goldman Sachs Downgrades Novartis (NVS) to Sell Over Risk Concer - GuruFocus
Novartis cut to Sell at Goldman Sachs on near-term risks (NVS:NYSE) - Seeking Alpha
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novartis, Pfizer and Bayer - The Globe and Mail
5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds - The Globe and Mail
Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver - sharewise.com
Novartis strikes $1.4bn deal for Tourmaline Bio - Proactive financial news
Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD) - Novartis
Palantir Deepens Industry Ties As Lear And Lumen Embrace Its AI Platforms - Sahm
Pfizer's 6.9% Yield & Bullish Signal: A Prime Buying Opportunity? - The Globe and Mail
Stomach Cancer Treatment Market Review 2020-2024 and Forecast 2025-2030 - GlobeNewswire Inc.
Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases - Ariva
Novo Nordisk Slowdown Weighs On Denmark's Economic Outlook - Sahm
BioArctic and Novartis Sign an Option, Collaboration and License Agreement Using BrainTransporter for an Upfront Payment of USD 30 Million Plus Additional Potential Milestones and Royalties - 富途牛牛
Drug Delivery Devices Market To Grow At 7.90% CAGR Through 2030, Driven By FDA Approvals And Pipeline Advances By Pfizer, J&J, Novartis, Medtronic, And Becton Dickinson Through 2030 Delveinsight - Menafn
Will EXEL's Share Repurchase Program Boost Value for Investors? - The Globe and Mail
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Finanzdaten der Novartis Ag Adr-Aktie (NVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.88%
0.54%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):